Vestar MR 35 MG


Vestar MR 35 MG


Stock Status:

In Stock

  • *Upload Prescription

    • (max file size 80 MB)



Trimetazidine Dihydrochloride



Long term treatment of angina pectoris



Trimetazidine dihydrochloride is the first inhibitor of 3-ketoacyl-CoA thiolase (KAT), a metabolic anti-ischemic drug that has been shown to be beneficial for all patients with coronary arteries. Trimetazidine dihydrochloride inhibits the fatty acid pathway by inhibiting 3-keto acyl CoA thiolase and transferring oxygen to the glucose pathway. Since the glucose pathway produces energy more efficiently, the same oxygen produces more energy, which makes the heart more active. In addition, the aerobic oxidation of glucose prevents the production of lactic acid, thus preventing angina pectoris.


Dosage & Administration

One tablet at mealtimes in the morning and evening



So far, there are no reports of drug interactions. In particular, there are no reports of interactions with beta-blockers, calcium channel blockers, nitrates, heparin, hypolipidemic drugs, or digitalis preparations.



Hypersensitivity to the active substance or to any of the excipients.


Side Effects

Rare cases of gastrointestinal disorders (nausea and vomiting).



No teratogenic effect was seen in animal studies; in the absence of clinical data, a risk of birth defect induction cannot be excluded; consequently, as a precaution, it is best not to prescribe the drug during pregnancy. In the absence of data on excretion of the drug in milk, breast-feeding is not recommended during treatment.



Trimetazidine is not a curative treatment for angina attacks, nor is it the initial treatment for unstable angina. It is also not a treatment for myocardial infarction.


Therapeutic Class

Other Anti-anginal & Anti-ischaemic drugs


Storage Conditions

Store at temperature not exceeding 30ºC in a dry place. Protect from light.


Pharmaceutical Name

Healthcare Pharmaceuticals Ltd.